2,3-dihydro-3-(hydroxymethyl)-1,4-benzodioxin-5-carboxaldehyde | 99059-06-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 英文名称: 2,3-dihydro-3-(hydroxymethyl)-1,4-benzodioxin-5-carboxaldehyde
• 英文别名: 3-hydroxymethyl-2,3-dihydro-benzo[1,4]dioxine-5-carbaldehyde；3-(Hydroxymethyl)-2,3-dihydro-1,4-benzodioxine-5-carbaldehyde
• CAS: 99059-06-0
• 化学式: C₁₀H₁₀O₄
• 分子量: 194.187
• InChiKey: CLCJSGMQFTVRDM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2,3-dihydro-3-(hydroxymethyl)-1,4-benzodioxin-5-carboxaldehyde 在 4-二甲氨基吡啶 、 四丁基氟化铵 、 sodium methylate 、 potassium carbonate 作用下， 以 四氢呋喃 、 吡啶 、 甲醇 、 二氯甲烷 、 xylene 为溶剂， 反应 26.5h， 生成 8-(4-Oxo-1-phenyl-1,3,8-triaza-spiro[4.5]dec-8-ylmethyl)-7,8-dihydro-3H-6,9-dioxa-3-aza-cyclopenta[a]naphthalene-2-carboxylic acid methyl ester
  参考文献：
  名称：

  Novel indolodioxanes with antihypertensive effects: potent ligands for the 5-HT1A receptor

  摘要：

  The synthesis and biological evaluation of a new family of tricyclic indolodioxanes is described. These compounds all contain the 2,3-dihydro-7H-1,4-dioxino[2,3-e]indole nucleus and bear substituents at the 2 and/or 8 positions. Thirteen members of this class were prepared and shown to be potent ligands for the 5-HTA receptor, with several compounds displaying subnanomolar inhibition constants. These compounds also bind to the dopamine D-2 receptor, but generally with higher inhibition constants than those for 5-HT1A. Certain members of this novel structural class show in vivo activity in the mouse hypothermia assay. One of these compounds, U-86192A, has been shown to have antihypertensive effects in the cat, completely eliminating sympathetic nerve discharge at 1 mg/kg iv and lowering mean arterial pressure to 50% pretreatment levels. These effects can be reversed by the administration of spiperone, indicating that U-86192A is acting via a central serotonergic mechanism.

  DOI：

  10.1021/jm00094a021
• 作为产物：
  描述：

  3-(oxiranylmethoxy)-2-(phenylmethoxy)benzaldehyde 在 palladium on activated charcoal 三乙胺 、 环己烯 作用下， 生成 2,3-dihydro-3-(hydroxymethyl)-1,4-benzodioxin-5-carboxaldehyde
  参考文献：
  名称：

  Novel indolodioxanes with antihypertensive effects: potent ligands for the 5-HT1A receptor

  摘要：

  The synthesis and biological evaluation of a new family of tricyclic indolodioxanes is described. These compounds all contain the 2,3-dihydro-7H-1,4-dioxino[2,3-e]indole nucleus and bear substituents at the 2 and/or 8 positions. Thirteen members of this class were prepared and shown to be potent ligands for the 5-HTA receptor, with several compounds displaying subnanomolar inhibition constants. These compounds also bind to the dopamine D-2 receptor, but generally with higher inhibition constants than those for 5-HT1A. Certain members of this novel structural class show in vivo activity in the mouse hypothermia assay. One of these compounds, U-86192A, has been shown to have antihypertensive effects in the cat, completely eliminating sympathetic nerve discharge at 1 mg/kg iv and lowering mean arterial pressure to 50% pretreatment levels. These effects can be reversed by the administration of spiperone, indicating that U-86192A is acting via a central serotonergic mechanism.

  DOI：

  10.1021/jm00094a021

文献信息

• [EN] HETEROCYCLYLCARBOXAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS<br/>[FR] DERIVES HETEROCYCLYLCARBOXAMIDES ET LEUR UTILISATION EN TANT QU'AGENTS THERAPEUTIQUES
  申请人：KNOLL AKTIENGESELLSCHAFT

  公开号：WO1997003071A1

  公开（公告）日：1997-01-30

  (EN) Compounds of formula (I), and pharmaceutically acceptable salts thereof in which A is methylene or O; B is methylene or O; g is 0, 1, 2, 3 or 4; R1 is an optional substituent; U is an alkylene chain optionally substituted by one or more alkyl; Q represents a divalent group containing nitrogen atoms; and T represents CO.HET, have utility in the treatment of central nervous system disorders, for example depression, anxiety, psychoses (for example schizophrenia), tardive dyskinesia, Parkinson's disease, obesity, hypertension, Tourette's syndrome, sexual dysfunction, drug addiction, drug abuse, cognitive disorders, Alzheimer's disease, senile dementia, obsessive-compulsive behaviour, panic attacks, social phobias, eating disorders and anorexia, cardiovascular and cerebrovascular disorders, non-insulin dependent diabetes mellitus, hyperglycaemia, constipation, arrhythmia, disorders of the neuroendocrine system, stress, prostatic hypertrophy, and spasticity.(FR) L'invention concerne des composés représentés par la formule (I) ainsi que des sels pharmaceutiquement acceptables de ces composés. Dans la formule (I), A est méthylène ou oxygène, B est méthylène ou oxygène, g vaut 1, 2, 3 ou 4, R1 est un substituant facultatif, U est une chaîne alkylène facultativement substituée par un ou plusieurs alkyles, Q représente un groupe divalent contenant des atomes d'azote et T représente le groupe CO.HET. Lesdits composés s'avèrent utiles dans le traitement des troubles du système nerveux central, tels que la dépression, l'anxiété, les psychoses (schizophrénie, par exemple), les dyskinésies tardives, la maladie de Parkinson, l'obésité, l'hypertension, la maladie de Gilles de la Tourette, les troubles de la sexualité, la toxicomanie, la pharmacodépendance, les troubles cognitifs, la maladie d'Alzheimer, la démence sénile, la psychonévrose obsessionnelle, les crises de panique, les névroses phobiques, les troubles de l'alimentation et l'anorexie, les troubles cardio-vasculaires et cérébro-vasculaires, le diabète sucré non-insulino-dépendant, l'hyperglycémie, la constipation, l'arythmie, les troubles du système neuro-endocrinien, le stress, l'hypertrophie prostatique et la spasticité.

  化合物的公式(I)，以及其中的药学上可接受的盐，其中A是亚甲基或氧原子；B是亚甲基或氧原子；g为0、1、2、3或4；R1是可选的取代基；U是一种可以被一个或多个烷基取代的烷基链；Q代表含有氮原子的二价基团；T代表CO.HET，可用于治疗中枢神经系统疾病，例如抑郁症、焦虑症、精神病（例如精神分裂症）、迟发性运动障碍、帕金森病、肥胖症、高血压、杜雷特综合症、性功能障碍、药物成瘾、药物滥用、认知障碍、阿尔茨海默病、老年性痴呆、强迫症行为、惊恐发作、社交恐惧症、进食障碍和厌食症、心血管和脑血管疾病、非胰岛素依赖性糖尿病、高血糖、便秘、心律失常、神经内分泌系统疾病、压力、前列腺肥大和痉挛症。
• [1,4]Benzodioxin and [1,4]benzoxazine derivatives
  申请人：HOECHST UK LIMITED

  公开号：EP0204148A2

  公开（公告）日：1986-12-10

  A compound of formula I in which formula R1 and R2, which may be the same or different, each represents a hydrogen atom, an alkyl group having from 1 to 4 carbon atoms or, together with the nitrogen atom to which they are attached, R1 and R2 form a 4 to 8-membered ring which may contain an oxygen atom or another nitrogen atom, which nitrogen atom may have an alkyl group having from 1 to 4 carbon atoms as substituent. X represents an oxygen atom or a group NR4 in which R4 represents a hydrogen atom, an alkyl group having from 1 to 4 carbon atoms, a phenyl group or a phenalkyl group, the alkyl moiety of which has from 1 to 4 carbon atoms. an alkyl, phenyl or phenalkyl group being unsubstituted or substituted, or R4 represents a nitrogen protecting group; m represents an integer of from 1 to 4; n represents the integer 1 or 2; and R3 represents a group of formula II, III, IV, V or VI in which formulae R5 represents a hydrogen atom or an alkyl group having from 1 to 4 carbon atoms; and R6 represents a hydrogen atom or an alkyl group having from 1 to 4 carbon atoms, an alkenyl group having from 2 to 4 carbon atoms, or an alkynyl group having 3 or 4 carbon atoms has histamine H-2 antagonist activity, and may be used to produce medicaments.

  一种式 I 的化合物 其中式 R1和R2（可以相同或不同）各自代表一个氢原子、一个具有 1 至 4 个碳原子的烷基，或者，R1和R2与它们所连接的氮原子一起形成一个 4 至 8 元环，该环可以包含一个氧原子或另一个氮原子，该氮原子可以具有一个具有 1 至 4 个碳原子的烷基作为取代基。 X 代表氧原子或基团 NR4，其中 R4 代表氢原子、具有 1 至 4 个碳原子的烷基、苯基或 苯烷基，其烷基具有 1 至 4 个碳原子。 未取代或取代的烷基、苯基或苯烷基，或 R4 代表氮保护基团； m 代表 1 至 4 的整数； n 代表 1 或 2 的整数；以及 R3 代表式 II、III、IV、V 或 VI 的基团 在这些式中 R5 代表氢原子或具有 1 至 4 个碳原子的烷基；以及 R6 代表氢原子或具有 1 至 4 个碳原子的烷基、具有 2 至 4 个碳原子的烯基或具有 3 或 4 个碳原子的炔基具有组胺 H-2 拮抗剂活性，可用于生产药物。
• Discovery of 2,3-Dihydro[1,4]dioxino[2,3-<i>g</i>]benzofuran Derivatives as Protease Activated Receptor 4 (PAR4) Antagonists with Potent Antiplatelet Aggregation Activity and Low Bleeding Tendency
  作者：Panpan Chen、Cai Chen、Yizheng Zheng、Fangjun Chen、Zhaojun Liu、Shenhong Ren、Hangyu Song、Tongdan Liu、Zhipeng Lu、Hongbin Sun、Yi Kong、Haoliang Yuan

  DOI：10.1021/acs.jmedchem.3c02099

  日期：2024.4.11

  benefited greatly from antiplatelet therapy. However, hemorrhage risk of antiplatelet agents cannot be ignored. Herein, we describe the discovery of 2,3-dihydro[1,4]dioxino[2,3-g]benzofuran compounds as novel PAR4 antagonists. Notably, the isomers 36 and 37 with the chemotype of phenoxyl methylene substituted on the 2,3-dihydro-1,4-dioxine ring exhibited potent in vitro antiplatelet activity (IC50 = 26.13 nM

  动脉栓塞性疾病患者从抗血小板治疗中获益匪浅。然而，抗血小板药物的出血风险也不容忽视。在此，我们描述了 2,3-二氢[1,4]二恶英[2,3- g ]苯并呋喃化合物作为新型 PAR4 拮抗剂的发现。值得注意的是，化学型为苯氧基亚甲基在 2,3-二氢-1,4-二恶英环上取代的异构体36和37表现出有效的体外抗血小板活性（ 36的 IC 50 = 26.13 nM， 37的 IC 50 = 14.26 nM），并且显着改善人肝微粒体的代谢稳定性（BMS-986120 36时T 1/2 = 97.6 分钟，11.1 分钟）。 36还表现出良好的口服 PK 特征（小鼠： T 1/2 = 7.32 h 和F = 45.11%）。两者在浓度为 6 和 12 mg/kg 时均表现出有效的体外抗血小板活性，对凝血系统没有影响且出血倾向低。我们的工作将促进新型 PAR4 拮抗剂的开发，作为动脉栓塞更安全的治疗选择。
• ——
  作者：ALLEN R. M.、 FLETCHER S. R.

  DOI：——

  日期：——
• HETEROCYCLYLCARBOXAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS
  申请人：ABBOTT GmbH & Co. KG

  公开号：EP0839145B1

  公开（公告）日：2003-11-05